Phase II study with tacrolimus to prevent GVHD for reduced-intensity peripheral blood stem cell transplantation from an HLA-identical related donor
Phase 2
- Conditions
- Acute leukemia, Chronic leukemia, Myelodysplastic syndrome, Malignant lymphoma, Adult T cell leukemia/lymphoma
- Registration Number
- JPRN-UMIN000001146
- Lead Sponsor
- agoya Blood and Marrow Transplantation Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 26
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Positive for HIV antibody andor HBs antigen (2)T cell depleted transplantation (3)Pregnant or during breast feeding (4)Uncontrolled psychiatric disease (5)Uncontrolled active infection (6)Allergic history to drugs used in the present conditioning regimen or GVHD prophylaxis regimen (7)A history of intravenous chemotherapy within 21 days before transplantation (8)Cases that physicians judged as inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method